Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
University of Chicago
Incyte Corporation
Dana-Farber Cancer Institute
Institute of Hematology & Blood Diseases Hospital, China
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University College, London
Universitätsklinikum Hamburg-Eppendorf
Therapeutic Advances in Childhood Leukemia Consortium
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
M.D. Anderson Cancer Center
Alliance for Clinical Trials in Oncology
University of New Mexico
Therapeutic Advances in Childhood Leukemia Consortium
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Alliance for Clinical Trials in Oncology
Children's Oncology Group
Children's Oncology Group
SWOG Cancer Research Network
SWOG Cancer Research Network
OHSU Knight Cancer Institute
Gruppo Italiano Malattie EMatologiche dell'Adulto
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
BTG International Inc.
University Hospital Schleswig-Holstein
Therapeutic Advances in Childhood Leukemia Consortium
South Plains Oncology Consortium
Milton S. Hershey Medical Center
M.D. Anderson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Therapeutic Advances in Childhood Leukemia Consortium
Takeda
M.D. Anderson Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Jonsson Comprehensive Cancer Center
M.D. Anderson Cancer Center
Children's Oncology Group